Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2009 3
2010 1
2011 1
2012 2
2013 2
2014 2
2015 3
2016 6
2017 6
2018 11
2019 3
2020 6
2021 6
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

49 results
Results by year
Filters applied: . Clear all
Page 1
NAFLD-NASH: An Under-Recognized Epidemic.
Jennings J, Faselis C, Yao MD. Jennings J, et al. Among authors: yao md. Curr Vasc Pharmacol. 2018;16(3):209-213. doi: 10.2174/1570161115666170622074007. Curr Vasc Pharmacol. 2018. PMID: 28676024 Review.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP; Secukinumab in Crohn's Disease Study Group. Hueber W, et al. Among authors: yao md. Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668. Epub 2012 May 17. Gut. 2012. PMID: 22595313 Free PMC article. Clinical Trial.
Chassis and key enzymes engineering for monoterpenes production.
Zhang L, Xiao WH, Wang Y, Yao MD, Jiang GZ, Zeng BX, Zhang RS, Yuan YJ. Zhang L, et al. Among authors: yao md. Biotechnol Adv. 2017 Dec;35(8):1022-1031. doi: 10.1016/j.biotechadv.2017.09.002. Epub 2017 Sep 6. Biotechnol Adv. 2017. PMID: 28888552 Review.
49 results